10X Genomics

10X Genomics

TXG
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

TXG · Stock Price

USD 22.42+13.65 (+155.64%)
Market Cap: $2.6B

Historical price data

Market Cap: $2.6BPatents: 20Founded: 2012Employees: 1000-5000HQ: Pleasanton, United States

Overview

10X Genomics' mission is to master biology to advance human health by providing essential infrastructure for modern biological research. The company has achieved market leadership with its Chromium, Xenium, and Visium platforms, which are cited in over 10,000 publications and used by thousands of researchers globally. Its strategy focuses on expanding its integrated hardware, software, and chemistry ecosystem to drive adoption in both research and translational markets, including pharmaceutical drug development and AI-driven cell modeling.

OncologyImmunologyNeuroscienceDevelopmental Biology

Technology Platform

Integrated platforms for single-cell and spatial genomics analysis, utilizing proprietary microfluidic partitioning (GEM technology), in situ hybridization, and whole-transcriptome capture to profile biology at cellular and subcellular resolution.

Funding History

3
Total raised:$460M
IPO$350M
Series B$55M
Series A$55M

Company Timeline

2012Founded

Founded in Pleasanton, United States

2013Series A

Series A: $55.0M

2015Series B

Series B: $55.0M

2019IPO

IPO — $350.0M